Highlighting Phase III Buntanetap Data & Embracing a More Holistic Approach to Neurodegenerative Disease Targeting
Time: 3:30 pm
day: Conference Day One PM
Details:
- Showcasing phase III success in improving cognition in Alzheimer’s disease (as measured by ADAScog) as well as movement and function in Parkinson’s (as measured by MDS-UPDRS)
- Outlining the cascade of events that follow Buntanetap-induced mRNA inhibition
- Leveraging its impact on several brain targets to emphasize the need for novel, more holistic drug approaches
